Digital
3rd - 4th November 2022

MarketsandMarkets Next-Gen Bioprocessing Global Virtual Conference (Time zone: CET)

Devising Effective Manufacturing & Quality Control Methods of Cell Therapies

Over the last 50 years, the bioprocessing industry has witnessed tremendous change, overcoming many challenges to increase efficiency and productivity throughout the development and manufacturing process. These efforts have been particularly focused to elicit major advancements for cell lines, culture media, and downstream processes used to produce therapeutics.

MarketsandMarkets is extremely delighted to announce its “ MarketsandMarkets Next-Gen Bioprocessing Virtual Conference scheduled to be held on 6th- 7th October 2022. The conference is designed for having interactive discussions in cell culture, scale-up, continuous biomanufacturing, recovery, purification, process and product characterization, formulation, case studies in analytics and stability. The conference also includes interactive breakout sessions, solutions and services supporting the rapidly growing bioprocessing industry. The event will witness the participation of decision makers from the pharmaceutical industry who are shaping the future of the bioprocessing industry.

WHAT TO EXPECT

Key Highlights

CELL CULTURE & BIOPRODUCTION

  • Protein synthesis and cell line development
  • Bioproduction 4.0
  • Bioprocess development strategies
  • Process monitoring and control
  • Bioproduction innovations

DOWNSTREAM PROCESSING & CONTINUOUS BIOMANUFACTURING

  • Upstream and downstream process optimization
  • Enhancing protein purification
  • Biomanufacturing 2030: The latest manufacturing shift
  • Pharma 4.0 trends and new drug delivery strategies
  • Commercial manufacturing case studies

CELL AND GENE THERAPY ANALYTICS & MANUFACTURING

  • Cell & Gene therapy analytics and characterization
  • Emerging analytical methods & Quality Control
  • AAV scale-up and manufacturing
  • Cell & Gene therapy process development
  • Navigating cell & gene therapy CMC and comparability

Who Should Attend?

CEO’s, CSO’s, COO’s, Presidents, Vice Presidents, Directors, Investigators, Heads, Managers, Principal scientists, Scientists, Professors, Lecturers, Group Heads & Researchers

From Pharmaceuticals/Therapeutics/Cell-Gene therapy-based companies.
Academics:
Universities/ Research Labs/Research Institutes  

• Working on:

  • Bioprocess development
  • Process development
  • GMP/Manufacturing
  • Cellular Therapy
  • Gene Therapy
  • Quality Control
  • Cell Engineering
  • Scale up Bioprocessing
  • Scale down bioprocessing
  • Fermentation
  • Cell Therapy
  • Cell culture operations
  • mRNA type therapeutics
  • ATMP (Advanced therapy medicinal products)
  • CAR T-cell therapy
  • Monoclonal antibodies (mAbs)
  • Viral vectors

 

Why Attend ?

  • Participate in discussions with experts on how technology implementation can be improved
  • Attracting and retaining world-class pharma and biotech talent
  • Improve the efficiency of bio-manufacturing by engaging in environmentally sustainable methods
  • Resolve common contamination and R&D challenges
  • Discover the latest technology implementations in the industry
  • Discover best-in-class solutions during the workshop sessions
  • Interactive panel discussions

CONFERENCE AGENDA
Enquire Now

Sponsor/Exhibit Delegate
CONFERENCE SPEAKERS
Advisors
Dimitrios A. Lamprou
Dimitrios A. Lamprou
Professor (chair) of Biofabrication and Advanced Manufacturing, Queen’s University Belfast
Speakers
Dimitrios A. Lamprou
Dimitrios A. Lamprou
Professor (chair) of Biofabrication and Advanced Manufacturing, Queen’s University Belfast
John Maher
John Maher
Scientific Founder and Chief Scientific Officer, Leucid Bio
Paula Meleady
Paula Meleady
Associate Director, National Institute for Cellular Biotechnology
Ioanna Tzani
Ioanna Tzani
Postdoctoral Researcher, The National Institute for Bioprocessing Research and Training
Pedro Silva Couto
Pedro Silva Couto
Post-Doctoral Research Fellow, University College London
Andrew Splevins
Andrew Splevins
Senior Development Director, CMC, Evox Therapeutics Ltd
Joseph M. Roig
Joseph M. Roig
Associate Technical Director, Apheresis | Global MSAT Cell Therapy Development and Operations, Bristol Myers Squibb
Itai Benhar
Itai Benhar
Professor, Tel Aviv University
Please contact [email protected] for speaking opportunity
PAST EVENT GALLERY